Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | LPL | P06858 | 8/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24788875 | 0.88 | P4HB (0.39) | P4HBLIPGLPLESR2AAK1 | |
| SCHEMBL15778480 | 0.85 | LIPG (0.42) | P4HBLIPGLPLESR2AAK1 | |
| SCHEMBL19510909 | 0.81 | LIPG (0.39) | P4HBLIPGLPLESR2AAK1 | |
| SCHEMBL21458804 | 0.79 | AAK1 (0.45) | P4HBAAK1HIF1ANLRP3 | |
| SCHEMBL21458801 | 0.79 | AAK1 (0.45) | P4HBAAK1HIF1ANLRP3 | |
| SCHEMBL28817123 | 0.79 | ESR2 (0.45) | P4HBLIPGLPLESR2AAK1 | |
| SCHEMBL28817124 | 0.79 | ESR2 (0.45) | P4HBLIPGLPLESR2AAK1 | |
| SCHEMBL10572 | 0.78 | LIPG (0.45) | P4HBLIPGLPLESR2AAK1 | |
| SCHEMBL473933 | 0.77 | GAA (0.54) | LIPGLPLAAK1CA1CA2 | |
| SCHEMBL1773884 | 0.77 | LIPG (0.46) | P4HBLIPGLPLESR2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | P4HB 2223/4885LIPG 858/4885LPL 1489/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | P4HB 2223/4885LIPG 858/4885LPL 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.